The state of prior immunosuppression in cancer enhances harmful effects (eg, sepsis). Despite advances in cancer treatment and sepsis management, the number of critically ill patients with cancer is increasing. Although the overall survival of patients with cancer experiencing septic shock has improved, the mortality observed in studies remains high.
Purpose
To determine the rate mortality from septic shock in patients with cancer by analyzing variations.
Design
Systematic review and meta-analysis.
Data Sources and Methods
A systematic search was performed in Medline, EMBASE, SCOPUS, Web of Science, and BIREME-BVS. Articles assessing mortality in patients with cancer experiencing septic shock (aged >18 years) were included. Review articles, letters to the editor, case reports, and conference proceedings were excluded. Methodological quality was assessed with the MInCir-Prognosis Scale and the Joanna Briggs Institute checklist to assess the risk of bias in prevalence studies.
Results
Overall mortality rate from septic shock was 58% (95% confidence interval [95%CI]: 54-63). Mortality rate during 2000–2010 and 2010–2024 was 61% (95%CI: 53-68) and 58% (95%CI: 52-63), respectively. Mortality rate by continent was 50% (95%CI: 24-76) in Africa, 61% (95%CI: 53-69) in Asia, 53% (95%CI: 48-59) in Europe, 64% (95%CI: 48-78) in North America, and 61% (95%CI: 37-82) in South America. Mortality rate in the intensive care unit was 53% (95%CI: 50-57). In-hospital mortality rate was 59% (95%CI: 49-68), and 50% (95%CI: 43-57), 61% (95%CI: 40-81), 69% (95%CI: 58-80) at 28–30, 90 and 180 days, respectively.
Conclusions
Despite advances in oncology and hematology, mortality among patients with cancer experiencing septic shock remains high and increases over time after discharge from the intensive care unit.
SungHFerlayJSiegelR, et al.Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249.
2.
CecconiMEvansLLevyM, et al.Sepsis and septic shock. Lancet.2018;392(10141):75–87.
3.
Martos-BenítezFDSoler-Morejón C deDLara-PonceKX, et al.Critically ill patients with cancer: A clinical perspective. World J Clin Oncol. 2020;11(10):809–835.
4.
BeniwalASinghOJunejaD, et al.Clinical course and outcomes of cancer patients admitted in medical ICU with sepsis. J Intensive Care Soc. 2023;24(4):351–355.
5.
DelgadoAGuddatiAK. Infections in hospitalized cancer patients. World J Oncol. 2021;12(6):195–205.
6.
BakkerJKattanEAnnaneD, et al.Current practice and evolving concepts in septic shock resuscitation. Intensive Care Med.2022;48(2):148–163.
7.
CuencaJAManjappacharNKRamírezCM, et al.Outcomes and predictors of 28-day mortality in patients with solid tumors and septic shock defined by third international consensus definitions for sepsis and septic shock criteria. In: Chest. Elsevier Inc., 2022: 1063–1073.
8.
ManjappacharNKCuencaJARamirezCM, et al.Outcomes and predictors of 28-day mortality in patients with hematologic malignancies and septic shock defined by sepsis-3 criteria. JNCCN J Natl Comprehen Cancer Netw. 2022;20(1):45–53.
9.
AwadWBNazerLElfarrS, et al.A 12-year study evaluating the outcomes and predictors of mortality in critically ill cancer patients admitted with septic shock. BMC Cancer. 2021;21(1):709. Epub ahead of print 1 December 2021. DOI: 10.1186/s12885 −021-08452-w.
10.
PageMJMcKenzieJEBossuytPM, et al.The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. Br Med J.2021;372:n 71. DOI: 10.1136/bmj.n 71.
11.
AromatarisEFernandezRGodfreyC, et al.Summarizing systematic reviews: methodological development, conduct and reporting of an Umbrella review approach. Int J Evid Based Healthc. 2015;13(3):132–140.
12.
ChumbitaMPuerta-AlcaldePGudiolC, et al.Impact of Empirical Antibiotic Regimens on Mortality in Neutropenic Patients with Bloodstream Infection Presenting with Septic Shock CLINICAL THERAPEUTICS, https:// journals.asm.org /journal/aac (2022).
13.
StataCorp. 2025. Stata Statistical Software: Release 19. College Station, TX: StataCorp LLC.
CamouFDidierMLeguayT, et al.Long-term prognosis of septic shock in cancer patients. Support Care Cancer.2020;28(3):1325–1333.
16.
Luz FiusaMMCosta-LimaCde SouzaGR, et al.A high angiopoietin-2/angiopoietin-1 ratio is associated with a high risk of septic shock in patients with febrile neutropenia. Crit Care.. 2013;17(4):R169. Epub ahead of print August 5, 2013. DOI: 10.1186/ cc12848.
17.
Islas-MuñozBVolkow-FernándezPSilva-ZamoraJ, et al.Mortality in patients with hematological malignancies, febrile neutropenia, and septic shock. J Infect Dev Ctries. 2024;18(2):235–242.
18.
JammeMDaviaudFCharpentierJ, et al.Time course of septic shock in immunocompromised and nonimmunocompromised patients. Crit Care Med. 2017;45(12):2031–2039.
19.
KangJHanMHongSB, et al.Effect of adjunctive corticosteroid on 28-day mortality in neutropenic patients with septic shock. Ann Hematol. 2019;98(10):2311–2318.
20.
LarchéJAzoulayÉFieuxF, et al.Improved survival of critically ill cancer patients with septic shock. Intensive Care Med. 2003;29(10):1688–1695.
21.
Borgne PLeFeuillassierL, et al.Comparison of short-and long-term mortality in patients with or without cancer admitted to the ICU for septic shock: A retrospective observational study. Cancers (Basel). 2022;14(13):3196. Epub ahead of print 1 July 2022. DOI: 10.3390/cancers14133196.
22.
LeeMRLaiCLChanKA. Intensive care unit admission and survival in stage IV cancer patients with septic shock: A population-based cohort study. J Cancer. 2019;10(14):3179–3187.
23.
LeeJHHanWHImHJ, et al.Effects of early initiation of polymyxin B hemoperfusion therapy in patients with cancer with refractory septic shock. J Clin Med.2024;13(4):1009. Epub ahead of print 1 February 2024. DOI: 10.3390/ jcm13041009.
24.
LemialeVPonsSMirouseA, et al.Sepsis and septic shock in patients with malignancies: A groupe de recherche respiratoire en réanimation onco- hématologique study. Crit Care Med. 2020;48(6):822–829.
25.
McDonnellECollinsRHernandezM, et al.Effect of hydrocortisone versus methylprednisolone on clinical outcomes in oncology patients with septic shock. J Oncol Pharm Pract.2021;27(1):54–62.
26.
MokartDSanniniABrunJP, et al.N-terminal pro-brain natriuretic peptide as an early prognostic factor in cancer patients developing septic shock. Crit Care. 2007;11(2):R37. Epub ahead of print March 14, 2007. DOI: 10.1186/ cc5721.
27.
MokartDSaillardCZemmourC, et al.Early prognostic factors in septic shock cancer patients: A prospective study with a proteomic approach. Acta Anaesthesiol Scand. 2018;62(4):493–503.
28.
De MontmollinETandjaoui- LambiotteYLegrandM, et al.Outcomes in critically ill cancer patients with septic shock of pulmonary origin. Shock. 2013;39(3):250–254.
29.
MouradMChow-ChineLFaucherM, et al.Early diastolic dysfunction is associated with intensive care unit mortality in cancer patients presenting with septic shock. Br J Anaesth. 2014;112(1):102–109.
30.
NathanNSculierJPAmeyeL, et al.Sepsis and septic shock definitions in patients with cancer admitted in ICU. J Intensive Care Med. 2021;36(3):255–261.
31.
NazerLAl-ShaerMHawariF. Drug utilization pattern and cost for the treatment of severe sepsis and septic shock in critically ill cancer patients. Int J Clin Pharm. 2013;35(6):1245–1250.
32.
NazerLAlnajjarTAl-ShaerM, et al.Evaluating the effectiveness and safety of hydrocortisone therapy in cancer patients with septic shock. J Oncol Pharm Pract.2014;21(4):274–279.
33.
NazerLHRimawiDHawariFI. Evaluating the predictive value of lactate in patients with cancer having septic shock. J Intensive Care Med. 2018;35(8):789–796.
34.
Ñamendys-SilvaSAGonzález-HerreraMOTexcocano-BecerraJ, et al.Clinical characteristics and outcomes of critically ill cancer patients with septic shock. QJM : An Int J Med. 2011;104(6):505–511.
35.
ParkHYSuhGYJeonK, et al.Outcome and prognostic factors of patients with acute leukemia admitted to the intensive care unit for septic shock. In: Leukemia and Lymphoma. Vol 492008:1929–1934.
36.
PèneFPercheronSLemialeV, et al.Temporal changes in management and outcome of septic shock in patients with malignancies in the intensive care unit. Crit Care Med. 2008;36(3):690–696.
37.
RamziJMohamedZYosrB, et al.Predictive factors of septic shock and mortality in neutropenic patients. Hematology. 2007;12(6):543–548.
38.
RasheedMKhanYHMujtabaG, et al.Assessment of clinical features and determinants of mortality among cancer patients with septic shock of pulmonary origin: A prospective analysis. Postgrad Med J.2020;96(1135):277–285.
39.
RavettiCGMouraADVieiraÉL, et al.STREM-1 predicts intensive care unit and 28-day mortality in cancer patients with severe sepsis and septic shock. J Crit Care. 2015;30(2):440.e7–440.e13.
40.
RegazzoniCJIrrazabalCLunaCM, et al.Cancer patients with septic shock: Mortality predictors and neutropenia. Support Care Cancer.2004;12(12):833–839.
41.
SchnellDBessetSLenglinéE, et al.Impact of a recent chemotherapy on the duration and intensity of the norepinephrine support during septic shock. Shock. 2013;39(2):138–143.
42.
WangJWeiSRDingT, et al.Continuous renal replacement therapy with oXiris ® in patients with hematologically malignant septic shock: A retrospective study. World J Clin Cases. 2023;11(26):6073–6082.
43.
WuYFPanYTangQ, et al.Early administration of dobutamine in the treatment of septic shock patients with tumor-a retrospective comparative cohort study. Ann Transl Med. 2022;10(15):828–828.
44.
YangYLengJChenR, et al.Correlation between early brain natriuretic peptide level and mortality in cancer patients with septic shock. Ann Palliat Med. 2021;10(4):4214–4219.
45.
YooJJungYAhnJH, et al.Incidence and clinical course of septic shock in neutropenic patients during chemotherapy for gynecological cancers. J Gynecol Oncol. 2020;31(5):1–12.
46.
ZuberBTranTCAegerterP, et al.Impact of case volume on survival of septic shock in patients with malignancies. Crit Care Med. 2012;40(1):55–62.
47.
VincentJLSakrYSprungCL, et al.Sepsis in European intensive care units: Results of the SOAP study. Crit Care Med. 2006;34(2):344–353.
48.
HernándezGOspina- TascónGADamianiLP, et al.Effect of a resuscitation strategy targeting peripheral perfusion Status vs Serum lactate levels on 28-day mortality among patients with septic shock: the ANDROMEDA-SHOCK randomized clinical trial. In: JAMA - Journal of the American Medical Association. American Medical Association. 2019: 654–664.
49.
ReinhartKDanielsRKissoonN, et al.Recognizing sepsis as a global health priority — A WHO resolution. N Engl J Med.2017;377(5):414–417.
50.
HernandezGBellomoRBakkerJ. The ten pitfalls of lactate clearance in sepsis. Intensive Care Med. 2019;45(1):82–85.
51.
LibertiMVLocasaleJW. The warburg effect: How does it benefit cancer cells?Trends Biochem Sci.2016;41(3):211–218.
52.
FathiMMarkazi -MoghaddamNRamezankhaniA. A systematic review on risk factors associated with sepsis in patients admitted to intensive care units. Aust Crit Care.2019;32(2):155–164. DOI: 10.1016/j.aucc.2018.02.005.
53.
NesselerNDefontaineALauneyY, et al.Long-term mortality and quality of life after septic shock: A follow-up observational study. Intensive Care Med. 2013;39(5):881–888.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
